The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
The market size for glucagon-like peptide (GLP) -1 agonists weight loss drugs has seen considerable growth recently. The market size will increase from $13.38 billion in 2024 to $15.63 billion in 2025, with a compound annual growth rate (CAGR) of 16.9%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Industry?
The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Global Market is projected to reach a size of $28.91 billion by 2029, growing at a compound annual growth rate (CAGR) of 16.6%.
Download Your Free Sample of the 2025 Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
The key drivers in the glucagon-like peptide (glp)-1 agonists weight loss drugs market are:
• Increasing demand for effective weight loss solutions
• Expansion of drug indications beyond diabetes
• Rising investments in research and development
• Growing adoption of personalized medicine and heightened awareness through direct-to-consumer marketing
Global Market Segmentation: Identifying Major Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Industry Segments
The glucagon-like peptide (GLP)-1 agonists weight loss drugs market covered in this report is segmented –
1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs
2) By Route of Administration: Parenteral, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
Pre-order the 2025 Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
The key trends in the glucagon-like peptide (glp)-1 agonists weight loss drugs market are:
• Development of oral Glucagon-Like Peptide (GLP)-1 formulations is an emerging trend in the market.
• Advancements in sustained-release drug delivery is a significant trend shaping the future of the market.
• Integration of digital health tools for monitoring is a key trend for the market's future growth.
• Use of artificial intelligence in drug discovery and development, and innovation in peptide engineering for enhanced efficacy, are witnessing growing trends in the market.
Who Are the Top Competitors & Leading Players in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
Major players in the glucagon-like peptide (glp)-1 agonists weight loss drugs market are:
• Pfizer Inc.
• Roche Holding AG
• Merck & Co. Inc
• Amgen Inc.
• Eli Lilly and Company
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd
• Boehringer Ingelheim
• Jiangsu Hengrui Medicine Co. Ltd
• BioAge Labs
• Hanmi Pharmaceutical
• Innovent Biologics Inc.
• Viking Therapeutics Inc.
• Structure Therapeutics Inc.
• Zealand Pharma A/S
• Regor Therapeutics Inc.
• I-Mab Biopharma (Shanghai) Co. Ltd.
• Altimmune Inc.
• TheracosBio LLC.
• Oramed Pharmaceuticals
Regional Dominance: Which Area Leads the Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024
